Genentech

Genentech Builds Biologics Facility in California

Genentech, the US biotech arm of Swiss pharma giant Roche, is building a new small-batch biologics manufacturing facility at its Oceanside campus in California, USA. Groundbreaking took place on Feb. 10.

Bill Anderson to Be Bayer CEO from June 1

Bowing to growing pressure from activist investors with different missions, the supervisory board of tradition-steeped German pharmaceuticals and agrochemicals player Bayer has announced the appointment of a new CEO to succeed embattled incumbent Werner Baumann — a year before the end of the current chief executive’s regular term.

Genentech Takes Jecure Therapeutics

FDA Approves Genentech Flu Drug

Affimed and Genentech in Immunotherapy Pact

Roche Sues Pfizer to Block Herceptin Copy

Genentech Returns Cancer Drug Rights to NewLink

US Firms Urge Trump to Uphold Paris Accord

Genentech Buys Rights to Hanmi’s Cancer Drug

ISPE Recognizes Leaders in Drug Shortage Prevention

Genentech’s Bladder Cancer Drug Wins US Approval

FDA Approves Drug for Leukemia Subset

DCAT Week ’16

Roche to buy US Biotech Firm InterMune for $8.3 Billion

Roche Alzheimer's Drug Fails Main Goals in Mid-stage Study

Codexis Reports Fourth Quarter and Full Year 2013 Results

Roche Wins FDA Approval for Breakthrough Leukemia Drug

Roche Takes Its Hunt For A New Chairman Further Afield

Alexion Valuation Could Choke Any Roche Bid

GlaxoSmithKline to Use Immunocore Drug Technology

Fast Climbing Biotech Regeneron Still Has Room to Grow

Long-serving Roche Chairman to Step Down Next Year

Roche Says US Allows it to Tap Adult Tamiflu Reserves

Roche Hires U.S. Academic to Revitalise Research Unit

Biotech M&A at 4-Year High as Pharma Faces Expiring Patents

U.S. Health Advisers Back Two New Eye Treatments

After Roche Merger, Biotech Tail Wags Big Pharma Dog

Roche Revamps Research Ops, Cuts 1,000 U.S. Jobs

Fine Chemicals: The Top 10

Severin Schwan of Roche Sees Generic Companies and Innovators As Winners

Glaxosmithkline Says Roche's Herceptin Infringes Patents

Sanofi's Best Bet Still May Be Smaller Deals

White Knight Could Be Elusive For Genzyme